Caligan Partners Lp Acquires 5,300 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) Director Caligan Partners Lp acquired 5,300 shares of the firm’s stock in a transaction that occurred on Tuesday, May 19th. The shares were bought at an average price of $59.98 per share, for a total transaction of $317,894.00. Following the completion of the purchase, the director owned 8,138,951 shares in the company, valued at $488,174,280.98. This trade represents a 0.07% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Liquidia Stock Performance

NASDAQ:LQDA opened at $61.97 on Friday. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.03 and a current ratio of 2.22. Liquidia Corporation has a 52-week low of $11.85 and a 52-week high of $62.30. The firm has a market cap of $5.51 billion, a price-to-earnings ratio of 442.67 and a beta of 0.41. The business’s fifty day moving average is $41.61 and its 200 day moving average is $37.08.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The company had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. Liquidia’s revenue was up 4187.1% on a year-over-year basis. Research analysts predict that Liquidia Corporation will post 2.97 EPS for the current year.

Institutional Investors Weigh In On Liquidia

Several institutional investors and hedge funds have recently bought and sold shares of the business. Farallon Capital Management LLC lifted its holdings in Liquidia by 1.1% in the 4th quarter. Farallon Capital Management LLC now owns 8,656,038 shares of the company’s stock worth $298,547,000 after buying an additional 90,400 shares during the period. Vanguard Group Inc. lifted its holdings in Liquidia by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 4,013,888 shares of the company’s stock worth $138,439,000 after buying an additional 52,671 shares during the period. Opaleye Management Inc. lifted its holdings in Liquidia by 9.5% in the 2nd quarter. Opaleye Management Inc. now owns 2,475,000 shares of the company’s stock worth $30,838,000 after buying an additional 215,000 shares during the period. Bank of America Corp DE lifted its holdings in Liquidia by 18.7% in the 1st quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after buying an additional 360,372 shares during the period. Finally, Caprock Group LLC raised its position in shares of Liquidia by 9.3% in the 4th quarter. Caprock Group LLC now owns 1,783,921 shares of the company’s stock worth $61,527,000 after acquiring an additional 151,832 shares in the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Wall Street Zen upgraded Liquidia from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 16th. HC Wainwright increased their target price on Liquidia from $55.00 to $67.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Needham & Company LLC increased their target price on Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a report on Monday, May 11th. BTIG Research increased their target price on Liquidia from $50.00 to $59.00 and gave the company a “buy” rating in a report on Monday, May 11th. Finally, Raymond James Financial restated a “strong-buy” rating on shares of Liquidia in a report on Thursday, March 5th. Three analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $49.33.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).